Association of free maternal and fetal ropivacaine after epidural analgesia for intrapartum caesarean delivery: a prospective observational trial
An erratum to this article was published (Int J Obstet Anesth, Nov 2024 ↗)
Authors' conclusion
The results of the present study suggest that determining the concentration of free ropivacaine in maternal blood may be a feasible option for estimating neonatal exposure to ropivacaine.
Study context
- Population
- Parturients with epidural analgesia undergoing intrapartum caesarean delivery after an epidural ropivacaine bolus128 screened
- Participants
- 39 participants
- Outcome
- Association between ropivacaine concentrations in maternal and fetal plasma
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Ropivacaine concentrations at delivery · At delivery
- Maternal venous total ropivacaine, mean ± SD
- 1402 ± 357 ng/ml
- Maternal venous free ropivacaine, mean ± SD
- 53 ± 46 ng/ml
- Fetal total ropivacaine, mean ± SD
- 457 ± 243 ng/ml
- Fetal free ropivacaine, mean ± SD
- 43 ± 27 ng/ml
- Correlation of maternal total and free ropivacaine concentrations
- r = 0.873; P < 0.0001
Observational data: associations, not effects.
Further findings
Epidural ropivacaine dose and treatment duration
- Epidural ropivacaine dose, median (25/75th percentile)
- 207 (166/276) mg
- Epidural treatment period, median (25/75th percentile)
- 577 (360/1010) min
Original publication
Association of free maternal and fetal ropivacaine after epidural analgesia for intrapartum caesarean delivery: a prospective observational trial. Int J Obstet Anesth. Published 11 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →